192 related articles for article (PubMed ID: 27627783)
1. CITED2 in breast carcinoma as a potent prognostic predictor associated with proliferation, migration and chemoresistance.
Minemura H; Takagi K; Sato A; Takahashi H; Miki Y; Shibahara Y; Watanabe M; Ishida T; Sasano H; Suzuki T
Cancer Sci; 2016 Dec; 107(12):1898-1908. PubMed ID: 27627783
[TBL] [Abstract][Full Text] [Related]
2. TACC2 (transforming acidic coiled-coil protein 2) in breast carcinoma as a potent prognostic predictor associated with cell proliferation.
Onodera Y; Takagi K; Miki Y; Takayama K; Shibahara Y; Watanabe M; Ishida T; Inoue S; Sasano H; Suzuki T
Cancer Med; 2016 Aug; 5(8):1973-82. PubMed ID: 27333920
[TBL] [Abstract][Full Text] [Related]
3. CITED2 modulates estrogen receptor transcriptional activity in breast cancer cells.
Lau WM; Doucet M; Huang D; Weber KL; Kominsky SL
Biochem Biophys Res Commun; 2013 Jul; 437(2):261-6. PubMed ID: 23811274
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of Cbp/P300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 2 inhibits cell division and increases apoptosis in gastric cancer.
Tang Z; He G; Xu J; Zhongfu L
J Surg Res; 2017 May; 211():1-7. PubMed ID: 28501104
[TBL] [Abstract][Full Text] [Related]
5. CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer.
van Agthoven T; Sieuwerts AM; Veldscholte J; Meijer-van Gelder ME; Smid M; Brinkman A; den Dekker AT; Leroy IM; van Ijcken WF; Sleijfer S; Foekens JA; Dorssers LC
Br J Cancer; 2009 Dec; 101(11):1824-32. PubMed ID: 19904269
[TBL] [Abstract][Full Text] [Related]
6. Pan-histone deacetylase inhibitor panobinostat sensitizes gastric cancer cells to anthracyclines via induction of CITED2.
Regel I; Merkl L; Friedrich T; Burgermeister E; Zimmermann W; Einwächter H; Herrmann K; Langer R; Röcken C; Hofheinz R; Schmid R; Ebert MP
Gastroenterology; 2012 Jul; 143(1):99-109.e10. PubMed ID: 22465428
[TBL] [Abstract][Full Text] [Related]
7. CITED2 affects leukemic cell survival by interfering with p53 activation.
Mattes K; Berger G; Geugien M; Vellenga E; Schepers H
Cell Death Dis; 2017 Oct; 8(10):e3132. PubMed ID: 29072699
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of CITED2 using short-hairpin RNA sensitizes cancer cells to cisplatin through stabilization of p53 and enhancement of p53-dependent apoptosis.
Wu ZZ; Sun NK; Chao CC
J Cell Physiol; 2011 Sep; 226(9):2415-28. PubMed ID: 21660965
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of CITED2 attenuates breast tumor growth, vessel formation and TGF-β-induced expression of VEGFA.
Jayaraman S; Doucet M; Kominsky SL
Oncotarget; 2017 Jan; 8(4):6169-6178. PubMed ID: 28008154
[TBL] [Abstract][Full Text] [Related]
10. CITED2 functions as a molecular switch of cytokine-induced proliferation and quiescence.
Chou YT; Hsieh CH; Chiou SH; Hsu CF; Kao YR; Lee CC; Chung CH; Wang YH; Hsu HS; Pang ST; Shieh YS; Wu CW
Cell Death Differ; 2012 Dec; 19(12):2015-28. PubMed ID: 22814619
[TBL] [Abstract][Full Text] [Related]
11. YWHAE promotes proliferation, metastasis, and chemoresistance in breast cancer cells.
Yang YF; Lee YC; Wang YY; Wang CH; Hou MF; Yuan SF
Kaohsiung J Med Sci; 2019 Jul; 35(7):408-416. PubMed ID: 31001932
[TBL] [Abstract][Full Text] [Related]
12. Expression of sex steroid receptors and their co-factors in normal and malignant breast tissue: AIB1 is a carcinoma-specific co-activator.
Hudelist G; Czerwenka K; Kubista E; Marton E; Pischinger K; Singer CF
Breast Cancer Res Treat; 2003 Mar; 78(2):193-204. PubMed ID: 12725419
[TBL] [Abstract][Full Text] [Related]
13. CITED2 Modulates Breast Cancer Metastatic Ability through Effects on IKKα.
Jayaraman S; Doucet M; Lau WM; Kominsky SL
Mol Cancer Res; 2016 Aug; 14(8):730-9. PubMed ID: 27216153
[TBL] [Abstract][Full Text] [Related]
14. TRIM44 Is a Poor Prognostic Factor for Breast Cancer Patients as a Modulator of NF-κB Signaling.
Kawabata H; Azuma K; Ikeda K; Sugitani I; Kinowaki K; Fujii T; Osaki A; Saeki T; Horie-Inoue K; Inoue S
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885545
[TBL] [Abstract][Full Text] [Related]
15. Expression of XB130 in human ductal breast cancer.
Li J; Sun W; Wei H; Wang X; Li H; Yi Z
Int J Clin Exp Pathol; 2015; 8(5):5300-8. PubMed ID: 26191231
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome c1 as a favorable prognostic marker in estrogen receptor-positive breast carcinoma.
Sato A; Takagi K; Miki Y; Yoshimura A; Hara M; Ishida T; Sasano H; Suzuki T
Histol Histopathol; 2019 Dec; 34(12):1365-1375. PubMed ID: 31149728
[TBL] [Abstract][Full Text] [Related]
17. Nucleobindin 2 in human breast carcinoma as a potent prognostic factor.
Suzuki S; Takagi K; Miki Y; Onodera Y; Akahira J; Ebata A; Ishida T; Watanabe M; Sasano H; Suzuki T
Cancer Sci; 2012 Jan; 103(1):136-43. PubMed ID: 21988594
[TBL] [Abstract][Full Text] [Related]
18. Nicotinamide N-methyltransferase enhances chemoresistance in breast cancer through SIRT1 protein stabilization.
Wang Y; Zeng J; Wu W; Xie S; Yu H; Li G; Zhu T; Li F; Lu J; Wang GY; Xie X; Zhang J
Breast Cancer Res; 2019 May; 21(1):64. PubMed ID: 31101119
[TBL] [Abstract][Full Text] [Related]
19. CITED2 is a novel direct effector of peroxisome proliferator-activated receptor γ in suppressing hepatocellular carcinoma cell growth.
Cheung KF; Zhao J; Hao Y; Li X; Lowe AW; Cheng AS; Sung JJ; Yu J
Cancer; 2013 Mar; 119(6):1217-26. PubMed ID: 23212831
[TBL] [Abstract][Full Text] [Related]
20. CITED2 silencing sensitizes cancer cells to cisplatin by inhibiting p53 trans-activation and chromatin relaxation on the ERCC1 DNA repair gene.
Liu YC; Chang PY; Chao CC
Nucleic Acids Res; 2015 Dec; 43(22):10760-81. PubMed ID: 26384430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
